Profil
Michael Alfieri worked as a Controller at Merrimack Pharmaceuticals from 2014 to 2017.
He then worked as a Controller & Executive Director-Finance at Anika Therapeutics from 2010 to 2014.
In 2017, he worked as a Vice President-Finance at Radius Health.
In 2018, he worked as VP-Finance, Chief Financial & Accounting Officer at Genocea Biosciences.
Mr. Alfieri received his undergraduate and graduate degrees from Bentley University.
Anciens postes connus de Michael Alfieri
| Sociétés | Poste | Fin |
|---|---|---|
| RADIUS HEALTH, INC. | Corporate Officer/Principal | 01/05/2018 |
| MERRIMACK PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01/01/2017 |
| ANIKA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/07/2014 |
| GENOCEA BIOSCIENCES, INC. | Directeur Financier/CFO | 05/03/2019 |
Formation de Michael Alfieri
| Bentley University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| ANIKA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
